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tory-associated DRVs could be linked to immunosuppressant, antineoplastic,
anticoagulant and diabetes therapy, while physiologic-associated DRVs were at-
tributed to cardiovascular therapies and NSAIDS. CONCLUSIONS: Significant pro-
portions of laboratory and physiologic abnormalities contribute to DRVs and are
consistently linked to specific drugs. These therapies could be potential targets for
enhanced medication monitoring initiatives to proactively avert potential DRVs.
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OBJECTIVES: Unintentional exposures to potent opioid medications by young chil-
dren can cause severe illness or death. An oral film formulation of buprenorphine/
naloxone was introduced in the United States (US) in September 2010. The
RADARS®System Poison Center program collects data about exposure to opioid
medications, including patient age, reason for exposure, specific formulation, and
medical outcome; in 2011Q4, 48/57 US poison centers provided data. We sought to
determine unintentional exposure rates and associated medical outcomes for bu-
prenorphine/naloxone tablets and oral film among children less than 6 years old.
METHODS: RADARS System Poison Center program case counts and medical out-
comes for unintentional exposures to buprenorphine/naloxone tablets and oral
film among children aged 0 – 5 years from October 1, 2010 – December 31, 2011 were
analyzed. To account for drug availability in the community, rates were standard-
ized using unique recipients of a dispensed drug (URDD) per year-quarter. Negative
binomial regression was used to estimate rates and confidence intervals.RESULTS:
Exposures to buprenorphine/naloxone tablets (average 0.68 cases/1,000 URDD; 95%
CI: 0.64 – 0.73) were more common than exposures to oral film (average 0.08 cases/
1,000 URDD; 95% CI: 0.07 – 0.10; rate ratio 8.1; 95% CI: 6.5 – 10.0; p  0.0001). Major
medical outcomes or death were reported in 0/92 (0%) oral film exposures and
19/869 (2.2%) tablet exposures (p0.24). CONCLUSIONS: Among children aged 0 – 5
years, unintentional exposures to buprenorphine/naloxone oral film are less fre-
quent than exposures to buprenorphine/naloxone tablets after adjustment for
drug availability. Major medical outcomes and death were uncommon with either
formulation and there were no deaths involving buprenorphine/naloxone oral film.
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OBJECTIVES: Rotavirus is the one of important disease for Turkey. It was reported
that 500.000 child admitted to hospitals due Rotavirus in Turkey per year. Total cost
of Rotavirus to Turkish economy was reported as US$ 40 million per year. The aim
of study is reflects the government perspective attributed to investing in Rotavirus
Vaccination(RV) in Turkey, and how changes in morbidity and mortality influence
government expenditure over many generations. METHODS: The model applies a
generational accounting approach for estimating the inter-temporal fiscal impact
of policy changes with accounting for direct fiscal transfers between age cohorts
and the State during different life stages while simultaneously accounting for ro-
tavirus medical costs, and how rotavirus mortality and morbidity influence gov-
ernment fiscal transfers. Costs are expressed in US $(1 US$ 1.75 TL). The model is
constructed using Turkish life tables, rotavirus related and unrelated health care
costs, employment earnings adjusted for age and social parameters. The model
compares vaccinated and unvaccinated cohorts against rotavirus using discounted
net tax revenues for different vaccine cost like US$ 36,24 and 12. RESULTS: Dis-
counted Net Tax Revenue(DNTR) between vaccinated and unvaccinated cohorts
for vaccine cost US$ 12 was US$ 84 and US $ 98 million for 25 and 50 years, respec-
tively. DNTR for vaccine cost US$ 24 and US$ 36 were US$ 19 and US$ 33 million,
US$ (-) 45 and US$ (-) 32 million, respectively. Investing in rotavirus vaccination
represented return for government at year 25 and 50 for vaccine cost US$ 12 and
US$ 24. Vaccine cost US$ 36 didn‘t represent return for government.
CONCLUSIONS: Long-term government net tax revenues were sensitive to vaccine
prices, therefore it is an important determinant of economic value of the vaccine.
Investments in RV prevention could also deliver early cost-offsets related to the
reduced health care expenditure in Turkey.
PIH8
COMPARATIVE PHARMACOECONOMIC STUDY OF DISPOSABLE AND REUSABLE
GOWNS AND DRAPES
Yagudina R1, Kulikov A2, Metelkin I2
1First Moscow State Medical University named after I. M. Sechenov, Moscow, Moscow, Russia,
2First Moscow State Medical University named after I. M. Sechenov, Moscow, Russia
OBJECTIVES: By means of «Budget impact analysis» define what type of surgical
gowns and drapes: disposable or reusable, is more rational to apply in surgery.
METHODS: Budget impact analysis was provided. The study estimated direct costs:
expenses for reusable and disposable gowns and drapes usage, drug therapy and
late complications (peritonitis, sepsis, phlegmon and abscess) treatment. Effective-
ness data was taken from 2 clinical trials: «Moylan J.A., Fitzpatrick K.T., Davenport
K.E. Reducing wound infections. Improved gown and drape barrier perfomance.
Arch Surg. – 1987» and «Surgical site infection by surgical category and type of
incision - 5 years from July 2004 to June 2009, England». Risk of postoperative
complications development was the main effectiveness criterion. Two types of
surgical linen were compared: simple surgical sheet, as an example of reusable
surgical linen, and a set of disposable gowns ad drapes. RESULTS: It was estab-
lished that the use of disposable surgical linen provides more effectiveness in
comparison with reusable analogs. Calculation of total expenses for use of 2 com-
pared alternatives showed that use of disposable surgical linen is economically
more favorable (285,4 $ for 1 operation carrying out) in comparison with the appli-
cation of reusable surgical analogs (603,6 $). Transition to this alternative scheme
of medical care allows to buy additional number of surgical sets (1 673 sets during
one year), on the money saved as a result of this transition. Unifactor sensivity
analysis was carried out, which showed that results of our pharmacoeconomic
study were stable. CONCLUSIONS: Total costs of disposable surgical linen usage
(428 100 $ for 1 500 operation carrying out during 1 year) appeared to be much less,
than those of reusable analogs application (905 400 $). That is why disposable
gowns and drapes can be recommended as economic.
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OBJECTIVES: Apply probabilistic linkage to add menopause symptoms recorded in
a registry database to claims data, and compare health care utilizations and costs
among women with and without symptoms. METHODS: Menopausal women age
45 prescribed estrogen only hormone therapy from a large U.S. claims database
(04/01/2005-09/30/2008) were linked with the University of Michigan Women’s Reg-
istry Database menopausal group using probabilistic linkage, controlling for osteo-
porosis, gynecological disorders/procedures, genital infection, bladder/pelvic floor
support problem, gynecology system cancer, breast condition, gut condition, hor-
mone disorder, nerve problem, and other comorbidities (rheumatoid disease, de-
pression, blood clotting). After linkage, registry patients’ menopause symptoms
were added to claims database records. The same linkage procedures were re-
peated 250 times, the mean and 95% confidence interval (CI) of health care costs
and utilizations during the follow-up period were compared between women with
and without symptoms. RESULTS: Among 80 matched patients, 84% had at least
one symptom, with hot flashes being the most common. The average cost of pa-
tients with at least one symptom was much higher than of patients without symp-
toms ($13,570 [95% CI: $13,459-$13,680] vs. $3,391 [95% CI: $3,345-$3,436],
p-value0.001). Cost differences were mainly from inpatient ($1,997 [95% CI:
$1,925-$2,070], p-value0.001 vs. $247 [95% CI: $239-$254, p-value0.001), physi-
cian visit ($967 [95% CI: $961-$974], p-value0.001 vs. $248 [95% CI: $246- $251],
p-value0.001), and pharmacy costs ($3,676 [95% CI: $3,648-$3,704], p-value0.001
vs. $903 [95% CI: $890- $916], p-value0.001). Women with symptoms were more
likely to have inpatient (12.78% vs. 4.05%, P0.001), outpatient emergency room
(20.6% vs. 6.31%, p0.001), and physician visits (79.86% vs. 18.71%, p0.001).
CONCLUSIONS: Women with menopause symptoms incur higher health care uti-
lizations and costs than those without. Results suggest that symptoms can be an
important predictor of economic outcomes. Therefore, it would be beneficial to
control for them using probabilistic linkage to bridge the gap between registry and
claims data.
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OBJECTIVES: To evaluates and compares the cost effectiveness of 2mg dienogest
versus gonadotropin-releasing hormone analogs (GnRH-a) for endometriosis treat-
ment. Some treatments only eliminate endometriosis symptoms while others
shrink and reduce lesions in addition to symptom treatment. In this context, di-
enogest was compared to the class of GnRH analogs, which are used in Turkey for
both symptomatic treatment and as a contributor to shrinkage/reduction of the
endometriotic lesions.METHODS: The population consisted of women age 18 to 49
eligible for GnRH-a treatment. GnRH-a treatment included leuprolide acetate (3
months intramuscular / subcutaneous injection 11.25mg, 1 syringe/box) and goserelin
acetate implant (3.6 mg 1 syringe/box). A Markov model was used to simulate three health
outcomes: treatment response, unresponsive to treatment and death. Costs were
assessed and compared between the 2mg dienogest group versus the selected
GnRH-a group over a 2-year time period. Clinical endpoints were quality adjusted
life years (QALY) and mean response time (50% improvement in Visual Analog
Scale[VAS] pain score) in health status when a patient responded to treatment.
Model output was calculated as incremental cost per QALY and per respondent
years gained. RESULTS: A 2-year model was utilized for GnRH-a therapy and sup-
porting treatment, and a 1-year model for treatment without supportive therapy.
Study results showed that dienogest had the same efficiency but lower health care
costs according to incremental cost per QALY and per respondent years gained for
both the 1 and 2-year models. Sensitivity analysis for treatment response and
regression rate also showed that 2mg dienogest was a more cost-effective treat-
ment option than GnRH-a agents. CONCLUSIONS: Results demonstrate that 2mg
dienogest is a more cost-effective option to treat endometriosis compared with
both GnRH-a agents. This result may assist with reimbursement plan selection for
endometriosis treatment from payers’ perspectives.
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